Sitko Bradley 的 Form 4 申報
XOMA Royalty Corp（XOMA），2026/7/14 申報
- 申報編號
- 0001193125-26-303722
- 申報時間
- 2026/7/14 21:45 ET
- 交易日
- 2026/7/14
- 申報延遲
- 當天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 9 筆非衍生性交易、4 筆衍生性交易。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Sitko BradleyCIK 0001959809 | 高階主管（投資長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/14 | Common Stock | J其他處分 | −83,765 | –F2,F3,F4 | – | 0 | 直接 | |
| 2026/7/14 | 8.625% Series A Cumulative Perpetual Preferred Stock | D交回公司處分 | −313 | –F2,F5 | – | 0 | 直接 | |
| 2026/7/14 | Depositary Shares - 8.375% Series B Cumulative Stock | D交回公司處分 | −7,045 | –F2,F6 | – | 0 | 直接 | |
| 2026/7/14 | Common Stock | J其他處分 | −1,287 | –F2,F3 | – | 0 | 間接 | |
| 2026/7/14 | Common Stock | J其他處分 | −75 | –F2,F3 | – | 0 | 間接 | |
| 2026/7/14 | Common Stock | J其他處分 | −75 | –F2,F3 | – | 0 | 間接 | |
| 2026/7/14 | Common Stock | J其他處分 | −1,500 | –F2,F3 | – | 0 | 間接 | |
| 2026/7/14 | 8.625% Series A Cumulative Perpetual Preferred Stock | D交回公司處分 | −82 | –F2,F5 | – | 0 | 間接 | |
| 2026/7/14 | Depositary Shares - 8.375% Series B Cumulative Stock | D交回公司處分 | −2,000 | –F2,F6 | – | 0 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/14 | Common Stock | D交回公司處分 | −300,000 | $0.00 | $0 | 0 | 直接 | |
| 2026/7/14 | Common Stock | D交回公司處分 | −250,000 | $0.00 | $0 | 0 | 直接 | |
| 2026/7/14 | Common Stock | D交回公司處分 | −41,112 | $0.00 | $0 | 0 | 直接 | |
| 2026/7/14 | Common Stock | D交回公司處分 | −23,488 | $0.00 | $0 | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
表 I 有 9 筆交易的價格引用這則附註。
- F3
At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").
表 I 有 5 筆交易的價格引用這則附註。
- F4
At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
表 I 有 2 筆交易的價格引用這則附註。
- F6
Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
表 I 有 2 筆交易的價格引用這則附註。